The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Rituximab-Induced Serum Sickness Is More Frequent in Autoimmune Diseases

Rituximab-Induced Serum Sickness Is More Frequent in Autoimmune Diseases

September 2, 2019 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Rituximab-induced serum sickness (RISS) occurs when rituximab-treated patients experience tissue deposition of immune complexes, prompting a delayed hypersensitivity reaction. A systematic review published in 2015 identified 33 cases of RISS documented in 25 articles, finding that RISS occurred in patients with autoimmune conditions, as well as those with hematological malignancies. Moreover, some patients with RISS had human anti-chimeric antibodies directed against the murine component of rituximab. Although the serum sickness typically resolved within days, physicians occasionally reported substantial mortality from progressive glomerulonephritis or severe neurological complications.1

You Might Also Like
  • Type 1 Diabetes Often Comes with Other Autoimmune Diseases
  • T Cells & Autoimmune Diseases
  • Rituximab May Help Pediatric Patients with SLE
Also By This Author
  • Disease Mimicry: Genetic Diseases Can Produce Rheumatic Symptoms

A recent retrospective study evaluating the medical records of French patients with RISS has found data that reinforces the understanding that patients will generally recover rapidly from RISS—even absent corticosteroid therapy. Guillaume Bayer, MD, of CHRU de Tours, France, and colleagues also found patients were at risk for recurrence of RISS. Thus, the investigators conclude their paper by suggesting clinicians reconsider the use of rituximab in patients who have had RISS. Their findings were published online July 3 in the European Journal of Internal Medicine.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“The present study reports 37 cases of well-documented RISS reported in France between 1998 and 2016, which is to our knowledge the largest series of RISS published so far,” write the authors in their discussion. “The most striking result for this series is that RISS occurred much more frequently (12-fold) when rituximab was prescribed to treat an autoimmune disease than a hematological malignancy. Although rituximab is not an approved treatment for patients with systemic lupus erythematosus (SLE), this pathology was the most representative autoimmune disorder in our study and furthermore seemed to be at higher risk for developing RISS (20-fold) than other autoimmune diseases.”

For 78% of patients in the series, physicians prescribed rituximab to treat an autoimmune disease. In half of the patients, serum sickness occurred after the first injection and had a median onset of 12 days. The most frequent manifestations of RISS were rheumatological symptoms (92%), fever (87%) and skin lesions (78%).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

In their paper, the investigators proposed that rituximab causes RISS by triggering B cell lysis, which releases intracellular antigens into the serum and prompts the subsequent formation of antigen-antibody complexes. They posit that such complex formation would be more likely to occur in patients with elevated autoantibody production. If their hypothesis is correct, then it would explain why patients with autoimmune disease have a higher incidence of RISS than patients with hematological malignancy. It would also explain the occurrence of RISS after a single rituximab injection.

“Finally, the fact that the efficacy of rituximab was not optimal in almost a quarter of our patients may be explained by the incomplete administration of treatment and the information bias related to the mode of data collection, but also the neutralization of rituximab within immune complexes,” write the authors. “Indeed, studies have described a correlation between [human anti-chimeric antibodies] and an incomplete clinical response to rituximab.”


Lara C. Pullen, PhD, is a medical writer based in the Chicago area.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

References

  1. Karmacharya P, Poudel DR, Pathak R, et al. Rituximab-induced serum sickness: A systematic review. Semin Arthritis Rheum. 2015 Dec;45(3):334–340.
  2. Bayer G, Agier MS, Lioger B, et al. Rituximab-induced serum sickness is more frequent in autoimmune diseases as compared to hematological malignancies: A French nationwide study. Eur J Intern Med. 2019 Jul 3. pii: S0953-6205(19)30192-X. [Epub ahead of print]

Pages: 1 2 | Multi-Page

Filed Under: Conditions, SLE (Lupus) Tagged With: rituximab, rituximab-induced serum sickness, Serum Sickness

You Might Also Like:
  • Type 1 Diabetes Often Comes with Other Autoimmune Diseases
  • T Cells & Autoimmune Diseases
  • Rituximab May Help Pediatric Patients with SLE
  • Genes Connect Parkinson’s Disease to Autoimmune Diseases

Simple Tasks

Learn more about the ACR’s public awareness campaign and how you can get involved. Help increase visibility of rheumatic diseases and decrease the number of people left untreated.

Visit the Simple Tasks site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)